0000950170-24-079689.txt : 20240701
0000950170-24-079689.hdr.sgml : 20240701
20240701164117
ACCESSION NUMBER: 0000950170-24-079689
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240627
FILED AS OF DATE: 20240701
DATE AS OF CHANGE: 20240701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Catinazzo Thomas
CENTRAL INDEX KEY: 0001818261
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39385
FILM NUMBER: 241091268
MAIL ADDRESS:
STREET 1: C/O RELAY THERAPEUTICS, INC.
STREET 2: 399 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Relay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001812364
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-370-8837
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-06-27
0001812364
Relay Therapeutics, Inc.
RLAY
0001818261
Catinazzo Thomas
C/O RELAY THERAPEUTICS, INC.
399 BINNEY STREET, 2ND FLOOR
CAMBRIDGE
MA
02139
false
true
false
false
Chief Financial Officer
true
Common Stock
2024-06-27
4
S
false
295
6.26
D
339508
D
Common Stock
2024-06-27
4
S
false
9078
6.24
D
330430
D
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Includes 304,929 shares underlying RSUs.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.
This transaction was executed in multiple trades at prices ranging from $6.12 to $6.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Thomas Catinazzo
2024-07-01